Exhibit 107
CALCULATION OF FILING FEE TABLES
Schedule 14A
(Form Type)
ChemoCentryx, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Transaction Valuation
Proposed Maximum Aggregate Value of Transaction | Fee Rate | Amount of Filing Fee | ||||
Fees to Be Paid | $3,983,687,165.35 | .0000927 | $369,287.80 | |||
Fees Previously Paid | — | — | ||||
Total Transaction Valuation | $3,983,687,165.35 | |||||
Total Fees Due for Filing | $369,287.80 | |||||
Total Fees Previously Paid | — | |||||
Total Fee Offsets | — | |||||
Net Fee Due | $369,287.80 |
Capitalized terms used below but not defined herein shall have the meanings assigned to such terms in the Agreement and Plan of Merger, dated as of August 3, 2022, by and among Amgen Inc., Carnation Merger Sub, Inc. and ChemoCentryx, Inc.
(i) | Title of each class of securities to which the transaction applies: Common stock, par value $0.001 per share (“Common Stock”), of ChemoCentryx, Inc. |
(ii) | Aggregate number of securities to which the transaction applies: As of the close of business on August 26, 2022, the maximum number of shares of Common Stock to which this transaction applies is estimated to be 78,445,258, which consists of: |
a. | 71,850,551 issued and outstanding shares of Common Stock; |
b. | 5,948,053 shares of Common Stock underlying Company Option Awards with exercise prices below $52.00; |
c. | 618,513 shares of Common Stock underlying Company RSU Awards; and |
d. | 28,141 shares of Common Stock estimated to be issuable pursuant to the Company ESPP after August 26, 2022 and prior to the Closing. |
(iii) | Per unit price or other underlying value of the transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): Solely for the purpose of calculating the filing fee, as of the close of business on August 26, 2022, the underlying value of the transaction was calculated as the sum of: |
a. | the product of 71,850,551 shares of Common Stock multiplied by the Merger Consideration of $52.00; |
b. | the product of 5,948,053 shares of Common Stock subject to issuance pursuant to outstanding Company Option Awards with exercise prices below $52.00, multiplied by $35.95 (which is the excess of $52.00 over $16.05, the weighted average exercise price of such Company Option Awards); |
c. | the product of 618,513 shares of Common Stock subject to issuance pursuant to outstanding Company RSU Awards multiplied by the Merger Consideration of $52.00; and |
d. | the product of 28,141 shares of Common Stock estimated to be issuable pursuant to the Company ESPP after August 26, 2022 and prior to the Closing multiplied by the Merger Consideration of $52.00. |
(such sum, the “Total Consideration”)
In accordance with Section 14(g) of the Exchange Act, the filing fee was determined by multiplying the Total Consideration by .0000927.